Investor Presentaiton

INO-3107 Phase 1/2 Study in RRP - IND Accepted; Granted Orphan Drug Designation TRIAL: INO-3107 (for HPV 6 and/or 11-caused RRP) Granted Orphan Drug Designation Phase 1/2 open- label, multicenter clinical study 26 26 x63 Target enrollment 4 doses of vaccine, 3 weeks apart on Day 0, Weeks 3, 6, 9 CELLECTRA-delivered INO-3107 plasmid encoded antigens Enrollment criteria: Subjects who have required at least two surgical interventions per year for the past three years for the removal of associated papilloma(s) Primary endpoint: A doubling or more in the time between surgical interventions following the first dose of INO-3107 relative to the frequency prior to study therapy INOVIO POWERING DNA MEDICINES

View entire presentation